Top

Published in:

01-04-2019 | Tyrosine Kinase Inhibitors | Original Article

Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer

Authors: Osman Köstek, Erdem Yılmaz, Muhammet Bekir Hacıoğlu, Nazım Can Demircan, Ali Gökyer, Sernaz Uzunoğlu, Nermin Tunçbilek, İrfan Çiçin, Bülent Erdoğan

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2019

Abstract

Purpose

To evaluate whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC).

Methods

Thirty-six patients treated with a tyrosine kinase inhibitor were included. Eighteen of them received sunitinib and the rest/remaining received pazopanib in the first line of mRCC treatment. Baseline and follow-up computed tomography studies of the patients were performed to measure cross-sectional areas (cm²) of muscle tissues.

Results

About 69% of patients were male and median age was 60 (49–68) years. Median time interval between two CT imagings was 6.1 (3.1–7.7) months and it was similar between the two groups (for sunitinib, 4.9 (2.5–6.9) months vs for pazopanib, 7.3 (3.2–9.5) months, p = 0.16, respectively). Disease control rate was 77.7% in all patients. Of these, 66.6% in sunitinib group was consisted of four partial responses and eight stable diseases. In addition, 88.8% in pazopanib group was consisted of three partial responses and 13 stable diseases. A significant decrease in SMA and LBM was observed after sunitinib therapy, whereas SMA and LBM values of pazopanib group did not change significantly (p = 0.02 and p = 0.70, respectively). No significant differences were observed between patients with sunitinib, and pazopanib group median PFS [11.9 (95% CI 6.1–17.6) vs 8.1 months (95% CI 7.2–9.1), respectively; p = 0.28] and median OS [28.6 (95% CI 24.3–32.9) vs 25.5 months (95% CI 18.9–52.7), respectively; p = 0.42]. Dose-limiting toxicities were significantly more frequent in sunitinib group than in pazopanib group (66.7% vs 22.2%, p = 0.02, respectively).

Conclusions

Loss of SMA and LBM with sunitinib was more substantial than with pazopanib. Treatment efficacies of both drugs were similar, but dose-limiting toxicity was more frequent in sunitinib group. Loss of SMA had no significant association with prognosis. Further studies are needed to clarify the possible association between SMA and prognosis in mRCC patients who receive sunitinib or pazopanib.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics 2018. CA 68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89(3):604–614CrossRefPubMed

Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A (2017) SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda (Based on November 2016 SEER data submission, posted to the SEER web site, April 2017)

Chang SF, Lin PL (2016) Systematic literature review and meta-analysis of the association of sarcopenia with mortality. Worldviews Evid Based Nurs 13(2):153–162CrossRefPubMed

Chang KV, Chen JD, Wu WT, Huang KC, Hsu CT, Han DS (2018) Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer 7(1):90–103. https://doi.org/10.1159/000484950 CrossRefPubMed

Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58–67. https://doi.org/10.1016/j.ejca.2015.12.030 CrossRefPubMed

Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21(8):1594–1598. https://doi.org/10.1093/annonc/mdp605 CrossRefPubMed

Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (Bethesda Md 1985) 85(1):115–122. https://doi.org/10.1152/jappl.1998.85.1.115 CrossRef

Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33(5):997–1006. https://doi.org/10.1139/h08-075 CrossRefPubMed

10.

Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, Ropert S, Delongchamps NB, Zerbib M, Goldwasser F (2013) Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108(5):1034–1041. https://doi.org/10.1038/bjc.2013.58 CrossRefPubMedPubMedCentral

11.

Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F (2016) Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol 195(1):26–32. https://doi.org/10.1016/j.juro.2015.08.071 CrossRefPubMed

12.

Lange AM, Lo HW (2018) Inhibiting TRK proteins in clinical cancer therapy. Cancers. https://doi.org/10.3390/cancers10040105 CrossRefPubMedPubMedCentral

13.

Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6(9):734–745. https://doi.org/10.1038/nrd2380 CrossRefPubMed

14.

Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C (2003) Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46(7):1116–1119. https://doi.org/10.1021/jm0204183 CrossRefPubMed

15.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327–337PubMed

16.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin oncol 24(1):16–24CrossRefPubMed

17.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516–2524CrossRefPubMed

18.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. https://doi.org/10.1056/NEJMoa065044 CrossRefPubMed

19.

Motzer RJ, Figlin RA, Hutson TE, Tomczak P, Bukowski RM, Rixe O, Bjarnason GA, Kim ST, Chen I, Michaelson D (2007) Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 25(18_suppl):5024–5024. https://doi.org/10.1200/jco.2007.25.18_suppl.5024 CrossRef

20.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. https://doi.org/10.1056/NEJMoa1303989 CrossRefPubMed

21.

Rousseau B, Kempf E, Desamericq G, Boissier E, Chaubet-Houdu M, Joly C, Saldana C, Boussion H, Neuzillet C, Macquin-Mavier I (2016) First-line antiangiogenics for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Crit Rev Oncol Hematol 107:44–53CrossRefPubMed

22.

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Negrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D (2014) Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 32(14):1412–1418. https://doi.org/10.1200/jco.2013.50.8267 CrossRefPubMed

23.

Laguna MP (2017) Re: First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. J Urol 197(3 Pt 1):603. https://doi.org/10.1016/j.juro.2016.12.059 CrossRefPubMed

24.

Kim JH, Park I, Lee JL (2016) Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer Chemother Pharmacol 78(2):325–332CrossRefPubMed

25.

MacLean E, Mardekian J, Cisar LA, Hoang CJ, Harnett J (2016) Real-world treatment patterns and costs for patients with renal cell carcinoma initiating treatment with sunitinib and pazopanib. J Manag Care Spec Pharm 22(8):979–990PubMed

26.

Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK (2014) Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370(18):1769–1770CrossRefPubMed

27.

Fernandez-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A (2017) A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol 71(3):426–436. https://doi.org/10.1016/j.eururo.2016.11.020 CrossRefPubMed

28.

Cohen S, Nathan JA, Goldberg AL (2015) Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 14(1):58–74. https://doi.org/10.1038/nrd4467 CrossRefPubMed

29.

Schmidinger M, Wittes J (2015) First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES. Curr Opin Urol 25(5):395–401. https://doi.org/10.1097/mou.0000000000000207 CrossRefPubMed

30.

Makhov P, Naito S, Haifler M, Kutikov A, Boumber Y, Uzzo RG, Kolenko VM (2018) The convergent roles of NF-kappaB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell Death Dis 9(3):374. https://doi.org/10.1038/s41419-018-0388-1 CrossRefPubMedPubMedCentral

31.

Argiles JM, Lopez-Soriano FJ, Busquets S (2012) Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog 17(3):253–262. https://doi.org/10.1615/CritRevOncog.v17.i3.30 CrossRefPubMed

32.

Fanzani A, Conraads VM, Penna F, Martinet W (2012) Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle 3(3):163–179CrossRefPubMedPubMedCentral

33.

Spirina LV, Usynin EA, Yurmazov ZA, Slonimskaya EM, Kondakova IV (2017) Effect of targeted therapy with pazopanib on expression levels of transcription, growth factors and components of AKT/m-TOR signaling pathway in patients with renal cell carcinoma. Asian Pac J Cancer Prev 18(11):2977–2983. https://doi.org/10.22034/APJCP.2017.18.11.2977 CrossRefPubMedPubMedCentral

34.

Ishibashi K, Koguchi T, Matsuoka K, Onagi A, Tanji R, Takinami-Honda R, Hoshi S, Onoda M, Kurimura Y, Hata J, Sato Y, Kataoka M, Ogawsa S, Haga N, Kojima Y (2018) Interleukin-6 induces drug resistance in renal cell carcinoma. Fukushima J Med Sci 64(3):103–110. https://doi.org/10.5387/fms.2018-15 CrossRefPubMedPubMedCentral

35.

Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV (2012) Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8):827–837. https://doi.org/10.1016/S1470-2045(12)70241-3 CrossRefPubMed

36.

Carmichael C, Yuh BE, Sun V, Lau C, Hsu J, Saikia J, Liu X, Wilson T, Ferrell B, Pal SK (2013) Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors. Clin Genitourin Cancer 11(2):149–154CrossRefPubMed

Title: Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer
Authors: Osman Köstek
Erdem Yılmaz
Muhammet Bekir Hacıoğlu
Nazım Can Demircan
Ali Gökyer
Sernaz Uzunoğlu
Nermin Tunçbilek
İrfan Çiçin
Bülent Erdoğan
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Keywords: Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
Pazopanib
Sunitinib
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03779-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

Blockade of integrin β3 signals to reverse the stem-like phenotype and drug resistance in melanoma

ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study

Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate

SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines

Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study

Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel

Keynote webinar | Spotlight on antibody–drug conjugates in cancer